This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): kunecatechins, sinecatechins, Polyphenon E
Description: The active substance in Polyphenon E is a concentrate of catechines with a defined composition, extracted from green tea leaves. The mode of action of Polyphenon E involved in the clearance of genital and perianal warts is unknown.
Deal Structure: In 1997, Epitome Pharmaceuticals Ltd. licensed from Mitsui Norin Company, a patented method of treating external genital warts through the topical application of Polyphenon E green tea extract. MediGene acquired the basic rights to the active substance in Veregen from Epitome Pharmaceuticals in 1999.
Nycomed (Bradley) and MediGene
In January 2006, MediGene announced that it entered into a partnership agreement with Bradley Pharmaceuticals to commercialize Polyphenon E Ointment in the US. Bradley Pharmaceuticals will take on US promotion and commercialization of the drug for the treatment of genital warts. MediGene and Bradley also agreed upon a development partnership to examine the application of Polyphenon E Ointment for the treatment of other skin diseases.
Under the terms of the agreement, MediGene could receive successive milestone payments up to $69 MM, including a payment of $5 MM due upon signing of the contract. In addition, MediGene will receive royalties...See full deal structure in Biomedtracker
Partners: MediGene AG AbbVie Inc. Bial Meditrina Pharmaceuticals Laboratoires Expanscience S.A. Epitome Pharmaceuticals Ltd. Will-Pharma PharmaNova, Inc. Nordic Group BV Azanta A/S SynCore Biotechnology Co., Ltd IFC Group Taurus Pharma GmbH Kora Healthcare Endo International plc Pierre Fabre Medicament S.A.
Pink Sheet Veregen FDA Reviewers
Pink Sheet Veregen Clinical Development
Additional information available to subscribers only: